Management of cancer pain

Portenoy, Russell K.; Lesage, Pauline

doi:10.1016/s0140-6736(99)01310-0

Cited by 694 publications

(419 citation statements)

References 17 publications

Supporting

Mentioning

382

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of chronic pain in patients with advanced cancer is estimated at 70%-90% [14]. Bone metastases are a common cause of chronic pain, with pain resulting directly from expanding lesions, pathologic fracture, or damage to adjacent structures.…”

Section: Painmentioning

confidence: 99%

Symptom Management in Metastatic Breast Cancer

2011

View full text Add to dashboard Cite

Approximately 40,000 women die as a result of breast cancer each year and many more live with advanced disease. When breast cancer recurs, the goals of treatment often shift from one of cure to controlling the disease for as long as possible while palliating symptoms interfering with the patient's functional status and quality of life. This requires ongoing discussions with the patient and family about the goals of care. Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain. The purpose of this paper is to identify and provide an overview of the management of the most common symptoms in patients with breast cancer metastases.

show abstract

Section: Painmentioning

confidence: 99%

Symptom Management in Metastatic Breast Cancer

2011

View full text Add to dashboard Cite

show abstract

“…Because advances in cancer detection and therapy are extending the life expectancy of cancer patients, there is an increasing focus on improving patients' QOL. For many patients, pain is the first sign of cancer, and 30-50% of all cancer patients will experience moderate to severe pain (26). Cancer can cause pain at any time during its course, but the frequency and intensity of pain tend to increase during the advanced stages.…”

Section: Expressions Of Growth Factors In Tumor Stromal Tissues In Cgrp-mentioning

confidence: 99%

Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide

Toda

Suzuki²,

Hosono³

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

117

110

View full text Add to dashboard Cite

“…Seventy-five to ninety percent of terminal cancer patients cope with opiateresistant pain related to tumor progression. [28,29,36,39] Eighty-five percent of cancer patients experience severe pain in their final days. [43] Cancer pain is classified into three syndromes: somatic, visceral and neuropathic.…”

Section: Introductionmentioning

confidence: 99%

Peripheral cannabinoids attenuate carcinoma-induced nociception in mice

Guerrero

Quang

Dekker³

et al. 2008

Neuroscience Letters

View full text Add to dashboard Cite

We investigated the cannabinoid receptor (CBr) agonists Win55,212-2 (non-selective) and AM1241 (CBr2 selective) and the peripheral receptor (CBr1) in carcinoma-induced pain using a mouse model. Tumors were induced in the hind paw of female mice by local injection of a human oral squamous cell carcinoma (SCC). Significant pain, as indicated by reduction in withdrawal thresholds in response to mechanical stimulation, began at four days after SCC inoculation and lasted to 18 days. Local administration of Win55,212-2 (10 mg/kg) and AM1241 (10 mg/kg) significantly elevated withdrawal thresholds, indicating an antinociceptive effect. Ipsilateral expression of CBr1 protein in L5 DRG was significantly upregulated compared to ipsilateral L4 DRG and in normal tissue. These findings support the suggestion that cannabinoids are capable of producing antinociception in carcinoma-induced pain.

show abstract

Management of cancer pain

Cited by 694 publications

References 17 publications

Symptom Management in Metastatic Breast Cancer

Symptom Management in Metastatic Breast Cancer

Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide

Peripheral cannabinoids attenuate carcinoma-induced nociception in mice

Contact Info

Product

Resources

About